Thalidomide: Induction Therapy
Multiple myeloma (MM) is a clonal stem cell disorder characterized by the presence of a monoclonal protein in the serum or urine, osteolytic bone lesions, increased plasma cells in the bone marrow, anemia, renal insufficiency, and hypercalcemia.1,2 The initial treatment of patients with MM has gone through changes over the years. The current management concept is to increase remission rates, progression-free survival (PFS), overall survival, and quality of life since MM is still incurable.3,4 However, with the current availability of multiple targeted therapies with comparable and sometimes superior efficacy and improved survival, the side-effect profile and long-term toxicity has become a major factor.
High-dose therapy with autologous stem cell transplant as part of initial therapy is currently considered the standard of care for patients who are eligible for transplant.5,6It is therefore important to avoid stem cell toxic drugs as part of induction therapy in patients...
KeywordsMultiple Myeloma Deep Vein Thrombosis Eastern Cooperative Oncology Group Autologous Stem Cell Transplantation Complete Response Rate
- 7.Harousseau J-L, Marit G, Caillot D, et al. VELCADE/Dexamethasone (Vel/Dex) versus VA D as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): An interim analysis of the IFM 2005–01 randomized multicenter phase III trial. Blood 2006;108(11):56.CrossRefGoogle Scholar
- 9.Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–6.PubMedCrossRefGoogle Scholar
- 17.Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 19909;94 (Suppl 1):604a (A 2686).Google Scholar
- 24.Rajkumar SV, Hussein M, Catalano J, et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. Blood 2006;108(11):238a. Abstract 795.Google Scholar
- 26.Breitkreutz I, Lokhorst HM, Raab MS, et. al Thalidomide in newly diagnosed multiple myeloma: Influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007.Google Scholar
- 27.Myeloma Trialists' Collaborative Group. Combination chemotherapy versus mel-phalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16(12):3832–42.Google Scholar
- 29.Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W Glick JH. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997;79(8):1561–7.PubMedCrossRefGoogle Scholar
- 31.Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 2005;106(11):230a (A780).Google Scholar
- 32.Hulin C, Virion J, Leleu X et al. Comparison of melphalan-prednisone-thalido-mide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial. J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):8001.Google Scholar
- 33.Ludwig H, Drach J, Tóthová E, et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. J Clin Oncol 2005;23(16S):6537.Google Scholar